In This Article:
Morgan Stanley lowered the firm’s price target on NeoGenomics (NEO) to $10 from $17 and keeps an Equal Weight rating on the shares. The company’s Q1 miss was primarily driven by lower non-clinical revenue and lower than expected average unit price, says the analyst, who…